PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

·        Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients

·        Announcement comes after a recent European Respiratory Journal viewpoint by Qureight CSO identifying fibrosis quantification as the key structural imaging biomarker needed for antifibrotic trials

·        PIPE-791 targets lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

Forced Vital Capacity (FVC), the primary endpoint in PROPEL-IPF, provides an established measure of lung function in IPF patients. Qureight’s AI-powered Fibr8™ imaging biomarker complements FVC by measuring the extent of fibrosis visible on High-Resolution Computed Tomography (HRCT), providing an assessment of structural disease burden. By examining both physiological and quantitative imaging measurements, PROPEL-IPF will investigate treatment effects on both lung function and imaging-defined measures of fibrosis progression, potentially generating valuable evidence to support the development of imaging endpoints for future clinical trials.

PROPEL-IPF (NCT07284459) is a global, randomised, double-blind, placebo-controlled Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of once-daily oral PIPE-791 with 26 weeks of treatment in approximately 324 people with IPF. PIPE-791 targets the lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF.

Qureight recently published a Viewpoint in the European Respiratory Journal advocating for the integration of quantitative fibrosis measurements alongside established physiological endpoints in antifibrotic clinical trials1. PROPEL-IPF represents an important opportunity to try to advance this approach by potentially generating prospective evidence on the relationship between treatment-related changes in lung fibrosis and pulmonary function. This would strengthen the evidence base for quantitative CT as a sensitive measure of therapeutic response and support Qureight’s longer-term ambition to pursue formal regulatory qualification of imaging biomarkers as endpoints in antifibrotic drug development.

Simon Walsh, MD, PhD, Chief Scientific Officer, Qureight, commented: “PROPEL-IPF is a strong example of the endpoint model we believe the field needs: preserve FVC as the functional anchor, while measuring fibrosis directly on HRCT. The combination has the potential to help reveal whether a therapy is slowing the structural disease process as well as its downstream functional consequences.”

Timothy Watkins, MD, MSc, Chief Medical Officer, Contineum Therapeutics, added: “Qureight’s approach to quantitatively measure fibrosis could provide important insights in PROPEL-IPF. We are excited for our team to partner with the clinical scientists at Qureight, leveraging this imaging technology platform to enable lung-specific mechanistic insight into the effects of PIPE-791. Ultimately, this measure has the potential to serve as an additional means by which we can assess the impact of PIPE-791 treatment on underlying fibrosis pathology in IPF.“

  1. Press release (2 November 2026) Qureight publishes in the European Respiratory Journal calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026